3 results on '"Aliki Taylor"'
Search Results
2. Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe – a systematic review of the literature
- Author
-
D. Pillas, Aliki Taylor, Ragnar Linder, Johan Hansson, Fernanda Costa Svedman, and Moninder Kaur
- Subjects
Oncology ,medicine.medical_specialty ,recurrence ,Epidemiology ,Review ,survival ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,cancer ,In patient ,Stage (cooking) ,Stage specific ,business.industry ,Melanoma ,Incidence (epidemiology) ,Cancer ,medicine.disease ,stage ,Surgery ,Europe ,030220 oncology & carcinogenesis ,business ,cutaneous malignant melanoma - Abstract
Background Given the increasing incidence in cutaneous malignant melanoma (CMM) and the recent changes in the treatment landscape, it is important to understand stage-specific overall and recurrence-free survival patterns in Europe. Despite publications such as EUROCARE-5, there is limited information on stage-specific survival for CMM in Europe. Method We carried out a systematic literature review to provide an up-to-date summary of stage-specific survival and recurrence-free survival patterns in patients with CMM in Europe. Studies were included if they were published in Medline during the past 12 years and included information on stage-specific survival and/or recurrence in CMM. Results Of the 8,749 studies identified, 26 studies were included, representing nine countries. Collectively, the studies covered a population of 152,422 patients and included data from 1978 to 2011. Randomized clinical trials and single-center observational studies comprised the most common study designs, including five large registry-based studies. Stage-specific information for survival and recurrence varied: 5-year overall survival: 95%–100% (stage I), 65%–92.8% (stage II), 41%–71% (stage III), and 9%–28% (stage IV); 5-year relapse-free survival was reported less frequently: 56% (stage II), and 28%–44% (stage III). Studies reporting survival by sentinel node (SN) status reported 5-year overall survival as 80%–95% for negative SN (stage I/II) and 35%–75% for positive SN (stage III) status; recurrence-free survival at 5 years: 76%–90% for negative and 35%–58% for positive SN status. Some studies included comparisons of survival by key patient sociodemographic characteristics, suggesting that these have a substantial influence on survival and recurrence estimates. Conclusion The studies identified in this review show large variations in stage-specific overall and recurrence-free survival by study type and by country. Owing to differing study designs and populations, it is difficult to make detailed comparisons. Large population-based studies that include stage-specific survival and recurrence in Europe are therefore important.
- Published
- 2016
3. Retrospective analysis of KRAS status in metastatic colorectal cancer patients: a single-center feasibility study
- Author
-
Aliki Taylor, Trine Frøslev, Stephen Hamilton-Dutoit, Jonathan Montomoli, and Rune Erichsen
- Subjects
Oncology ,Pathology ,medicine.medical_specialty ,Colorectal cancer ,Population ,Single Center ,medicine.disease_cause ,survival ,Internal medicine ,KRAS ,medicine ,Retrospective analysis ,education ,neoplasms ,Original Research ,education.field_of_study ,Clinical and Experimental Gastroenterology ,business.industry ,Gastroenterology ,feasibility study ,registries ,colorectal neoplasms ,medicine.disease ,digestive system diseases ,Feasibility Studies ,Colorectal Neoplasms ,business - Abstract
Jonathan Montomoli,1 Stephen Jacques Hamilton-Dutoit,2 Trine Frøslev,1 Aliki Taylor,3 Rune Erichsen11Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 2Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark; 3Centre for Observational Research, Amgen, Uxbridge, UKBackground: The occurrence of KRAS mutations and their association with prognosis in metastatic colorectal cancer patients is not well documented in population-based studies.Objectives: To examine the feasibility of identifying archived colorectal cancer specimens, and through linkage with nationwide Danish population-based databases to investigate the prevalence of KRAS mutations and their association with colorectal cancer survival.Methods: We used the Danish Pathology Database to identify the physical location of primary (or in some cases secondary) tumor specimens from selected metastatic colorectal cancer patients referred to our hospital for palliative chemotherapy between November 1, 2008 and September 30, 2009. Routinely stored paraffin tissue blocks were obtained from the pathology archives of the originating hospital. KRAS mutation tumor status was assessed for each patient using the commercialized TheraScreen KRAS Mutation Kit. Using the unique identifier number, we linked the patients to the Danish National Registry of Patients and the Danish Civil Registration System to obtain data on date of first colorectal cancer diagnosis and follow-up status. We estimated prevalence of KRAS mutations and the 1-, 2-, and 5-year survival after colorectal cancer diagnosis using the Kaplan–Meier technique.Results: We identified 106 metastatic colorectal cancer patients (64% males). All were successfully linked to the registries, and archived tumor-tissue samples were obtained and analyzed in each case. The overall prevalence of KRAS mutations was 55%, and 1-, 2-, and 5-year overall survival after colorectal cancer diagnosis was 91%, 68%, and 25%, respectively.Conclusion: It is feasible to use Danish population-based registries to obtain archived tissue samples from metastatic colorectal cancer patients, and to estimate prevalence of KRAS mutation and subsequently evaluate the association with colorectal cancer survival.Keywords: feasibility study, KRAS, colorectal neoplasms, survival, registries
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.